Board Certification and Academic Information
||Pediatrics - Professor (Clinical)
Dr. Chatfield received her medical degree from the Medical College of Virginia at Virginia Commonwealth University. She completed her pediatric residency and pediatric pulmonary fellowship at the University of Colorado Health Sciences Center in Denver, Colorado. Upon completion of fellowship training, she completed a four year active duty tour with the United States Air Force in Biloxi Mississippi where she established the first pediatric pulmonary service in the Air Force. She was also the Director of the Tri-Services CF Affiliate Center at Keesler Medical Center and Director of Pediatric Critical Care Services at Keesler Medical Center. Dr. Chatfield accepted a position as an assistant professor of pediatrics on the clinical track at the University of Utah in 1995. Dr. Chatfield was initially the associate director for the Intermountain Cystic Fibrosis Center and was named the Director of this program in 1999. Dr. Chatfield was promoted to associate professor in 2001 and full professor in 2007.
Dr. Chatfield’s clinical research interests are centered on Quality Improvement in relation to Cystic Fibrosis. The Intermountain Cystic Fibrosis Center participated in the first Learning and Leadership Collaborative sponsored by the Cystic Fibrosis Foundation in 2003. The CF Center has continued to work towards improved outcomes through multiple quality improvement projects. These projects have focused on improvement in nutrition, improved education, infection control and treatment of pulmonary exacerbations. Dr. Chatfield has also worked extensively as a consultant to the Utah Department of Health Newborn Screening Advisory Committee and Genetics Advisory Committee to implement newborn screening for CF in 2009. Dr. Chatfield is a member of the CF Foundation newborn screening quality improvement group.
Dr. Chatfield has also been the Co-PI on the Cystic Fibrosis Foundation Therapeutic Development Center (TDC) Grant since 2006. As a TDC site, the Intermountain Cystic Fibrosis Center has had increased opportunities to participate Phase I and Phase II multi-center clinical trials. The Intermountain CF Center has a track record of excellent enrollment, accurate and careful participation in numerous critical clinical trials. Dr. Chatfield was the site PI for Vertex 08-770-103. This landmark study utilizes VX770 to potentiate the gating of defective CFTR in patients with G551D mutations. This pediatric study has completed enrollment and all study procedures. Based on the findings, Vertex Pharmaceuticals prepared a new drug application to the FDA which was approved in a little over two months from time of submission. This is be the first drug ever approved to target the basic defect causing disease in CF in a select population of CF patients. Dr. Chatfield is also an investigator on trials of Lumacaftor and Ivacaftor which will hopefully target a larger segment of the Cf population-those homozygous for F508del-the most common CF causing mutation. Dr. Chatfield has been the PI on a variety of epidemiologic as well as other drug intervention studies in pediatric patients. These include NIH, Cystic Fibrosis Foundation and industry funded studies.
Dr. Chatfield is the Medical Director for the Cystic Fibrosis Care Center at Primary Children’s Hospital. She works closely with administrators to develop and maintain the multidisciplinary care team and assure CF Foundation standards are being met. In this setting, Dr. Chatfield works with many allied health care providers and mentors them in clinical and educational pursuits. Dr. Chatfield gives regular lectures to nursing, other allied health and house officers on CF related issues. Dr. Chatfield has recently spoken on Newborn Screening at PCH Grand Rounds and traveled with the Health Department to give similar presentations. Dr. Chatfield has been an invited speaker at local, regional and national meetings.
Dr. Chatfield’s outpatient practice is primarily focused on CF care with CF Clinic being held three days per week. A special block of the clinic is reserved for newborn screen patients. Dr. Chatfield also attends on the general inpatient pulmonary service.